Metab Brain Dis 32(4):1073
Anything that helps reduce your stress levels has the potential to make it easier for you to respond to cravings with a clear head (instead of reaching for snacks) or get better sleep
Maitra, I., Serbinova, E., Trischler, H., and Packer, L
Adding the genetic test after your first month of therapy helps confirm you're on the right medication and dosing path for your unique biology
By binding to GLP-1 receptors in the pancreas, brain, and gut, semaglutide: Stimulates insulin release only when blood glucose is elevated, which significantly reduces hypoglycaemia risk compared to older diabetes drugs Suppresses glucagon reducing the livers release of stored glucose into the bloodstream Slows gastric emptying food leaves the stomach more slowly, producing prolonged fullness and reducing overall caloric intake Acts on the brains appetite centres reducing hunger signals and food cravings Mounjaro (Tirzepatide): Dual GLP-1 + GIP Receptor Agonist Tirzepatide activates the same GLP-1 receptor as semaglutide but also activates a second receptor: the glucose-dependent insulinotropic polypeptide (GIP) receptor
Indication and Usage Semaglutide is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of : 30 kg/m2 or greater (obesity) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia)
